psychiatry

A team of researchers has analysed data from more than 650,000 residents in Sweden and concluded that the genetic predisposition of peers - especially in high school - influences one's risk of developing anxiety, depression or drug abuse in the future. According to the authors, who publish the results in the American Journal of Psychiatry, this relationship appears "even after controlling statistically for whether peers were affected or not". 

Ketamine extended-release tablets are effective, safe and well tolerated in patients with depression resistant to other treatments, according to a phase 2 clinical trial. Compared to intranasal or intravenous use of ketamine, these oral tablets are easier to administer and would provide less dissociative intensity, lower risk of abuse and cardiovascular adverse effects, the authors write in Nature Medicine. 

The PsychENCODE consortium, established in 2015 and dedicated to illuminating the molecular mechanisms underlying schizophrenia, bipolar disorder, and autism spectrum disorder, presents findings based on the examination of human brains at the cellular level. The studies are published today in the journals Science, Science Translational Medicine and Science Advances.

The largest meta-analysis to date that studies the risk of children of people with a mental disorder also suffering from some type of mental disorder during their lifetime has been published, with Spanish participation. According to the study, the risk is more than double that of the rest of the population. To explain the study and resolve any doubts that may arise, the Science Media Centre Spain organised an information session with one of the authors, psychiatrist Joaquim Raduà.

Apps developed to treat depression may be beneficial in the management of severe and moderate cases. This is the conclusion of a review and meta-analysis that included 13 studies with up to 16 different apps. The results are published in the journal JAMA Network Open.

A meta-analysis, pooling the results of 40 previous studies - involving more than 310,000 children and adolescents in total - concludes that treatment rates for mental disorders in these age groups are "generally low, especially for depression and anxiety". The research, published in JAMA Network Open, shows that the treatment rate for any mental disorder is 38%, ranging from 31% for anxiety, 36% for depression, 49% for conduct disorders and 58% for attention deficit hyperactivity disorder (ADHD).

A phase 1 clinical trial has tested the use of psilocybin to treat anorexia nervosa. Ten women with the disorder were given 25 milligrams of the hallucinogen along with psychological support. The results show that the treatment is safe and tolerable. Four patients showed an improvement, but the authors acknowledge that, because of the small sample size and the absence of a control group, "the results are preliminary and further research is needed". The results are published in the journal Nature Medicine.

A commentary published last Friday in the journal Molecular Psychiatry, signed by more than 30 researchers, challenges the conclusions of the systematic review published in the same journal in July 2022, in which the authors concluded that there was no evidence that low serotonin levels cause depression. The researchers in the new paper blame the earlier study for flaws in methodology, among other weaknesses.

Researchers from FIDMAG Hermanas Hospitalarias and CIBERSAM have announced the development of an algorithm that detects the risk of schizophrenia from fingerprints with a reliability of 70 %. It has been tested on 700 patients with schizophrenia and 850 people without schizophrenia; validation studies are pending.

A phase 2 clinical trial has examined the use of the hallucinogen psilocybin in different amounts for the treatment of resistant depression. The results are published in the New England Journal of Medicine.